GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cassava Sciences Inc.
Shares of Cassava Sciences, a biotech company developing a drug for Alzheimer's disease, are extremely volatile. Their price is driven less by scientific data than by heated debates, accusations, and retail investors' belief in the possibility of a breakthrough.
Share prices of companies in the market segment - Neuro
Cassava Sciences is a biopharmaceutical company focused on developing a drug to diagnose and treat Alzheimer's disease. We classify it in the Neuroscience sector. The chart below shows the overall dynamics of this high-risk, yet socially significant, field.
Broad Market Index - GURU.Markets
Cassava Sciences is a biotech company developing a drug to diagnose and treat Alzheimer's disease. Despite the controversy, it remains a significant player and is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Cassava's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
SAVA - Daily change in the company's share price Cassava Sciences Inc.
For Cassava Sciences, Inc., which is developing a drug for Alzheimer's disease, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to the biotech risk assessment formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Cassava Sciences, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with SAVA, which focuses on Alzheimer's disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cassava Sciences is a biotech company developing a drug to treat Alzheimer's disease. Its shares are known for their extreme volatility, driven by conflicting data and public debate. It's a prime example of how a single story can create powerful market ripples.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cassava Sciences Inc.
Cassava Sciences' year-to-date performance is one of the most dramatic and controversial stories in biotech. Its 12-month market cap is extremely volatile and entirely dependent on news surrounding its Alzheimer's drug, simufilam. Its valuation is a constant struggle between hopes for a breakthrough and serious accusations against its data.
Annual dynamics of market capitalization of the market segment - Neuro
Cassava Sciences, Inc. is a biotech company developing a controversial drug for the treatment of Alzheimer's disease. Its stock price is extremely volatile and depends entirely on clinical trial results and regulatory decisions, making it one of the most speculative in the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cassava is one of the most controversial stories in biotech. Its stock price has nothing to do with the economy, but rather reflects the rollercoaster of hopes and accusations surrounding its Alzheimer's drug. The chart is a clear example of how investor sentiment can drive stocks.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cassava Sciences Inc.
Cassava Sciences is developing a drug for Alzheimer's disease, and its history is fraught with controversy. Its monthly performance is extremely volatile, a direct result of news about its clinical trials and the ongoing debate surrounding its data. The chart reflects these binary risks and high stakes.
Monthly dynamics of market capitalization of the market segment - Neuro
Cassava Sciences is a biotech company whose fate hinges entirely on developing a drug for Alzheimer's disease. Its path has been marked by both enormous optimism and serious criticism of its data. The chart below shows the dynamics of the biotech sector, where CNS drug development is the riskiest area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cassava Sciences is a biotech company developing a drug for Alzheimer's disease. Its shares are among the most volatile on the market, and their performance is 100% dependent on news about clinical trials and debates over the reliability of the data. Correlation with the market is zero; it's a pure bet on the scientific outcome.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cassava Sciences Inc.
Cassava Sciences, a biopharmaceutical company developing a drug for Alzheimer's disease, is experiencing extreme volatility. Its weekly stock price is a sharp reaction to any news about clinical trials, scientific publications, and regulatory announcements, reflecting the high stakes in this field.
Weekly dynamics of market capitalization of the market segment - Neuro
Cassava Sciences is working on a drug for Alzheimer's disease, making its shares extremely news-sensitive. This chart allows us to separate the hype surrounding its research from general trends in the neuroscience sector and understand how unique its investment story is compared to its peers.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cassava Sciences is developing a drug for Alzheimer's disease. Its shares are extremely volatile and driven by research news. The chart clearly demonstrates that Cassava's performance is almost uncorrelated with the market, existing in its own world of biotech hopes and disappointments.
Market capitalization of the company, segment and market as a whole
SAVA - Market capitalization of the company Cassava Sciences Inc.
Cassava Sciences' chart is one of the most polarized on the stock market, a battleground for the future of Alzheimer's treatment. Its extreme volatility reflects not just data, but a war of narratives: patients' hopes versus the accusations of skeptics. Every movement on this chart is a reaction to rumors, reports, and belief in a potential breakthrough.
SAVA - Share of the company's market capitalization Cassava Sciences Inc. within the market segment - Neuro
Cassava Sciences' market share in the neuroscience sector represents a promise of a breakthrough in Alzheimer's treatment. Its market share is highly volatile and directly dependent on clinical trial news. This metric reflects investor confidence in its scientific approach, not current sales.
Market capitalization of the market segment - Neuro
Cassava Sciences is at the epicenter of the Alzheimer's cure research. The chart below shows the overall market capitalization of the entire biotech sector. Its extremely volatile dynamics reflect the enormous hopes and crushing failures in this highly complex field of medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cassava Sciences is developing a drug to treat Alzheimer's disease. Its high but volatile market cap reflects both the enormous need for such a treatment and the high risks. The chart below shows the economic weight of companies researching a cure for this disease.
Book value capitalization of the company, segment and market as a whole
SAVA - Book value capitalization of the company Cassava Sciences Inc.
For Cassava Sciences, which is developing a drug for Alzheimer's disease, book value is its capital. The chart below isn't about factories, but about the financial resources it has to conduct crucial clinical trials. Its level shows how much fuel the company has on its path to a potential breakthrough.
SAVA - Share of the company's book capitalization Cassava Sciences Inc. within the market segment - Neuro
Cassava Sciences is a clinical-stage biotech company developing a drug for Alzheimer's disease. Its value lies in the potential of its drug, not its manufacturing facilities. Its tangible asset share will be minimal, emphasizing its focus on intangible assets: patents and research data.
Market segment balance sheet capitalization - Neuro
Cassava Sciences is a biotech company whose value is created in the labs developing a drug for Alzheimer's disease. It's a "light" model, based on science. The chart below shows how much the pharmaceutical industry relies on tangible assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Cassava Sciences' assets represent capital entirely focused on the development and clinical trials of a drug for the treatment of Alzheimer's disease. The company's book value is the financial expression of its hope for a breakthrough in one of the most complex areas of neuroscience. The chart illustrates the scale of this risky scientific bet.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cassava Sciences Inc.
Cassava Sciences is developing a drug for Alzheimer's disease. Its balance sheet is a cash cow for research. Its market capitalization is one of the most volatile in the sector, a roller coaster of investor hopes and doubts. The chart clearly shows how any news about clinical trials causes extreme movements in the company's valuation.
Market to book capitalization ratio in a market segment - Neuro
Cassava Sciences is developing a drug to treat Alzheimer's disease. This is one of the most risky and potentially lucrative areas in biotech. The chart shows an extremely high market valuation compared to the book value, reflecting not the current situation, but rather the investors' high hopes for a scientific breakthrough.
Market to book capitalization ratio for the market as a whole
Cassava Sciences is a biotech company developing a drug to treat Alzheimer's disease. The chart illustrates the enormous hopes and risks in this field. The company's market capitalization is a pure bet on the success of its clinical trials. It has no correlation to its tangible assets and can fluctuate tenfold based on research news.
Debts of the company, segment and market as a whole
SAVA - Company debts Cassava Sciences Inc.
Cassava Sciences is developing a drug to treat Alzheimer's disease, one of the most challenging areas in pharmaceuticals. Debt is a way for a biotech company in clinical trials to finance expensive and time-consuming research. This chart illustrates how the company secures resources to pursue a potential breakthrough.
Market segment debts - Neuro
Cassava Sciences is at the forefront of Alzheimer's disease drug development, one of the most complex challenges in modern medicine, requiring massive capital to conduct clinical trials. This chart provides insight into the financial norms of the pharmaceutical industry, which underscores Cassava's high-risk and capital-intensive pursuit of scientific breakthroughs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cassava Sciences Inc.
Cassava Sciences is focused on developing a cure for Alzheimer's disease, one of the most challenging areas in medicine. This chart shows the level of debt used to fund its research. For biotech investors, this is a critical metric, reflecting the company's financial risk amid uncertain clinical trial results.
Market segment debt to market segment book capitalization - Neuro
Developing drugs for neurodegenerative diseases like Alzheimer's, a focus for Cassava Sciences, is an extremely risky and expensive field. This chart shows how the biotech sector as a whole funds its long-term research. It allows one to assess a company's financial sustainability given the high costs and length of clinical trials.
Debt to book value of all companies in the market
Cassava Sciences is battling Alzheimer's disease, one of the riskiest and most capital-intensive challenges in biotech. Financing such developments always balances debt and investor confidence. This chart reflects how the market assesses their potential relative to the company's financial obligations.
P/E of the company, segment and market as a whole
P/E - Cassava Sciences Inc.
This metric for Cassava Sciences, a biopharmaceutical company developing a drug for Alzheimer's disease, reflects both enormous expectations and risks. Its value is determined not by current profits, but by investors' faith in a potential breakthrough in treating this disease. The chart is extremely sensitive to news about clinical trials.
P/E of the market segment - Neuro
This indicator represents the average valuation for the neuroscience-focused biotech sector, where Cassava Sciences operates. It reflects the overall level of hope and risk in this complex field. The chart serves as a barometer of investor sentiment toward the entire Alzheimer's drug development sector.
P/E of the market as a whole
Cassava Sciences is in the spotlight due to its development of a drug to treat Alzheimer's disease. Its shares are extremely volatile, and their movements depend solely on clinical trial data and regulatory decisions. This chart of overall market sentiment is almost irrelevant here. Cassava's valuation exists in its own universe, ruled by science and hope.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cassava Sciences Inc.
Cassava Sciences is a biotech company whose fate depends almost entirely on developing a drug to treat Alzheimer's disease. Its stock is extremely volatile due to conflicting data and controversies surrounding its research. This chart reflects a rollercoaster of speculative expectations: from high hopes for a breakthrough in the treatment of neurodegenerative diseases to serious doubts about its scientific approach.
%20P%2FE%20Cassava%20Sciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cassava-Sciences-Inc.&v=1772639129940 "Chart of the company's future (projected) P/E Cassava Sciences Inc.")
Future (projected) P/E of the market segment - Neuro
Cassava Sciences is a biotech company closely associated with the development of a drug to treat Alzheimer's disease. This is one of the most complex and anticipated areas in medicine, fraught with enormous risks. This chart reflects expectations for the sector, allowing one to assess how the market views Cassava's prospects compared to other neuroscience companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772639129973 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Cassava Sciences is developing a drug to treat Alzheimer's disease, one of the most complex challenges in modern medicine. For the company, the overall market sentiment, as reflected in this chart, is critical. High optimism and risk appetite among investors allow them to attract the hundreds of millions of dollars needed to conduct large-scale and lengthy clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772639130004 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cassava Sciences Inc.
Cassava Sciences is developing a drug to treat Alzheimer's disease, one of the most complex challenges in pharmaceuticals. This chart shows the financial costs of key clinical trials. The company's future profits depend entirely on the success of these studies, which are under the close scrutiny of the scientific community.
Profit of companies in the market segment - Neuro
Jerash Holdings (JRSH) is a clothing manufacturer for leading global brands with factories in Jordan. The company's profitability depends on orders from major retailers and labor costs. This chart reflects the state of the global textile industry, where pricing pressure from brands and competition between manufacturers significantly impact margins.
Overall market profit
Cassava Sciences is at the forefront of the fight against Alzheimer's disease, developing a potential treatment. Unlike most companies whose success depends on economic cycles, Cassava's value is determined solely by the results of clinical trials. This chart provides a backdrop that demonstrates how a scientific breakthrough can create value regardless of market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cassava Sciences Inc.
Cassava Sciences is a biotech company in the spotlight for its development of a drug to treat Alzheimer's disease. Its future profit forecasts are highly polarized and depend entirely on the results of clinical trials. This chart reflects the speculative and conflicting opinions of analysts about the company's chances of achieving a breakthrough in one of the most complex areas of medicine.
%20profit%20of%20the%20company%20Cassava%20Sciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cassava-Sciences-Inc.&v=1772639130120 "Graph of future (projected) profit of the company Cassava Sciences Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Cassava Sciences has taken on one of the most complex challenges in medicine—developing a cure for Alzheimer's disease. The company's future depends entirely on the success of its drug candidate. This chart shows the overall profitability forecasts for the entire neuroscience sector. It sets the stage for the scale of Cassava's bet: if successful, it will experience explosive growth.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772639130128 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Cassava Sciences is focused on developing drugs for Alzheimer's disease, making its success dependent on clinical trial results rather than the state of the economy. Nevertheless, the presented market forecast chart is important, as it impacts investor risk appetite, which determines the availability of funding for long-term biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772639130142 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cassava Sciences Inc.
Cassava Sciences is a biotech company focused on developing a drug to treat Alzheimer's disease. The company is in the spotlight due to its potential breakthrough and the controversy surrounding its data. Its minimum revenue estimate in this chart is a clear reflection of the hopes and risks associated with developing a cure for one of humanity's most devastating diseases.
P/S market segment - Neuro
Cassava Sciences is a clinical-stage biotech focused on developing a treatment for Alzheimer's disease. Its future revenue is entirely dependent on the success of clinical trials and regulatory approval. This chart shows the average valuation in the sector, reflecting the high risks and potential rewards the market is pricing in for such companies.
P/S of the market as a whole
Cassava Sciences is developing a drug to treat Alzheimer's disease, one of the most challenging areas in modern medicine. The company's valuation depends entirely on the results of clinical trials. This chart, showing average real revenue estimates, demonstrates the vast gap between the value of hope in biotech and the estimated stable revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cassava Sciences Inc.
Cassava Sciences is focused on developing a drug to treat Alzheimer's disease. This chart is a barometer of the company's hopes and risks. Its dynamics depend entirely on news about clinical trials. The high valuation reflects investors' belief in the enormous potential returns should its revolutionary drug be successful.
%20P%2FS%20Cassava%20Sciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cassava-Sciences-Inc.&v=1772639130209 "The graph of the company's future (projected) P/S Cassava Sciences Inc.")
Future (projected) P/S of the market segment - Neuro
Cassava Sciences is at the forefront of the fight against Alzheimer's disease, developing a drug aimed at restoring the structure of a key protein in the brain. The company's success could revolutionize treatment. This chart shows the enormous premium investors are willing to pay for Cassava's future sales, reflecting the high stakes and expectations surrounding its research.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772639130214 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
This chart reflects the hopes surrounding Alzheimer's disease treatment. Cassava Sciences is developing a drug aimed at restoring damaged protein structure in the brain. Despite the risks inherent in biotechnology, a potential breakthrough in this field could dramatically change the lives of millions of people and create a huge market, fueling long-term investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772639130217 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cassava Sciences Inc.
Cassava Sciences is a biotech company focused entirely on developing a drug for the treatment of Alzheimer's disease. While in clinical trials, it has not yet commercialized its lead candidate. This chart reflects its financial position, which is dependent on research funding, not revenue, which would only accrue if the drug is successful and approved.
Sales of companies in the market segment - Neuro
Cassava Sciences is at the forefront of the Alzheimer's disease cure search. The company is developing a drug aimed at restoring the structural function of a key protein in the brain. This chart illustrates the enormous size of the neurological disease drug market and the potential reward for the company that succeeds in developing an effective therapy.
Overall market sales
Cassava Sciences is a clinical-stage biopharmaceutical company focused on developing a drug to diagnose and treat Alzheimer's disease. Its valuation is entirely dependent on the results of clinical trials. This general economic outlook influences investor sentiment and their willingness to fund high-risk biotech companies with breakthrough potential.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cassava Sciences Inc.
Cassava Sciences is developing a drug for the treatment of Alzheimer's disease based on an innovative approach to restoring protein function. The company's future depends entirely on the results of clinical trials. This chart shows analysts' highly speculative revenue forecasts, which are betting on a potential breakthrough in the treatment of this devastating disease.
%20sales%20of%20the%20company%20Cassava%20Sciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cassava-Sciences-Inc.&v=1772639130235 "Schedule of future (projected) sales of the company Cassava Sciences Inc.")
Future (projected) sales of companies in the market segment - Neuro
Cassava Sciences is focused on developing a treatment for Alzheimer's disease, one of the most challenging areas in modern medicine. The company's future depends entirely on the results of clinical trials. This chart reflects forecasts for the entire neuroscience pharmaceutical segment, showing analysts' overall expectations for the development of this medical field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772639130251 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Cassava Sciences is a clinical-stage biotech company developing a drug for the treatment of Alzheimer's disease. Its future depends entirely on the results of its trials and regulatory approvals. This overall economic climate influences investor sentiment and their willingness to fund high-risk biotech projects with a potentially huge market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772639130264 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cassava Sciences Inc.
For Cassava Sciences, focused on developing a drug for Alzheimer's disease, this chart is a financial timeline of scientific research. It reflects the significant investments in clinical trials required to bring a revolutionary drug to market. It demonstrates the costs involved in achieving potential future revenue and value creation.
Market segment marginality - Neuro
Cassava Sciences is developing a drug to treat Alzheimer's disease, one of the most challenging areas in pharmaceuticals. Its financial performance reflects its significant investment in clinical research. This chart provides insight into the company's operating model and cost structure compared to other neuroscience biotechs.
Market marginality as a whole
Cassava Sciences is a biotech company in the clinical stage of developing a drug for the treatment of Alzheimer's disease. Their stock price is highly volatile and dependent on research news. This overall profitability chart has no direct bearing on their performance, as their future is determined solely by scientific data and regulatory decisions.
Employees in the company, segment and market as a whole
Number of employees in the company Cassava Sciences Inc.
Cassava Sciences is focused on developing a drug to treat Alzheimer's disease, which has attracted considerable attention. This chart shows the size of the team conducting large-scale and expensive clinical trials. The dynamics of the team's size directly reflect the intensity of R&D and investment in one of the most complex areas of modern medicine.
Share of the company's employees Cassava Sciences Inc. within the market segment - Neuro
Cassava Sciences is focused on developing a treatment for Alzheimer's disease. This chart shows the company's concentration of leading neuroscientists and clinicians in this complex field. Its team is at the forefront of science, attempting to solve one of the greatest medical mysteries of our time.
Number of employees in the market segment - Neuro
Cassava Sciences, Inc. is a biotechnology company focused on developing a drug to treat Alzheimer's disease. This chart shows the overall employment in the neuroscience research sector. It illustrates the enormous effort and resources devoted to fighting this disease, as well as the high level of risk and potential reward for companies like Cassava.
Number of employees in the market as a whole
Cassava Sciences is focused on developing a cure for Alzheimer's disease, one of the most challenging areas of modern medicine. The company's work requires the best minds in neuroscience and biochemistry. This overall employment chart indirectly reflects the state of capital-intensive R&D sectors, where investment in scientific talent is key to achieving breakthroughs in healthcare.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cassava Sciences Inc. (SAVA)
Cassava Sciences is a biotech company focused on developing a drug to treat Alzheimer's disease. The astronomically high market capitalization per employee, visible on the chart, is typical for biotech companies in the clinical trial stage. The market evaluates not current operations, but a potential blockbuster capable of changing the lives of millions and generating billions.
%20of%20the%20company%20Cassava%20Sciences%20Inc.%20(SAVA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cassava-Sciences-Inc.-SAVA&v=1772639130344 "Chart of market capitalization per employee (in thousands of dollars) of the company Cassava Sciences Inc. (SAVA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Cassava Sciences is focused on developing a cure for Alzheimer's disease. For a biotech company working on such a significant problem, its market capitalization reflects investors' expectations for the success of clinical trials. This metric demonstrates the enormous potential value the market places on the work of each member of its scientific team, even without current revenue.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772639130359 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Cassava Sciences is a clinical-stage biopharmaceutical company developing a drug to treat Alzheimer's disease. Its extremely high and volatile valuation per employee represents a direct bet by investors on the success or failure of a single key study. This chart illustrates the extreme risk and potential reward in biotech.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772639130370 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cassava Sciences Inc. (SAVA)
Cassava Sciences is a biotech company working on a drug to treat Alzheimer's disease. This is one of the most complex and capital-intensive areas of R&D. This chart illustrates the high cost of this research: it measures the net loss (clinical trial costs) per employee involved in this risky project.
%20Chart%20Cassava%20Sciences%20Inc.%20(SAVA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cassava-Sciences-Inc.-SAVA&v=1772639130377 "Company Profit Per Employee (in thousands of dollars) Chart Cassava Sciences Inc. (SAVA)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Cassava Sciences is a biotech company working on a drug for Alzheimer's disease. At the clinical stage, this metric is irrelevant, as the company is not profitable. The graph shows the industry standard, which SAVA could surpass many times over if successful. All the value is currently generated by a small scientific team, not by operational efficiency.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772639130392 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Cassava Sciences (SAVA) is a biotech company focused entirely on one of the most challenging challenges: finding a cure for Alzheimer's disease. Their business is high-risk, yet potentially revolutionary, R&D. This chart shows that, until the drug is commercialized, the entire research team is a cost center, not a profit center.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772639130399 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cassava Sciences Inc. (SAVA)
For Cassava Sciences, which is developing a drug to treat Alzheimer's disease, this chart represents investor expectations, not current revenue. If clinical trials are successful and the drug is approved, revenue per employee could become astronomical due to the huge potential market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cassava-Sciences-Inc.-SAVA&v=1772639130417 "Sales chart per company employee Cassava Sciences Inc. (SAVA)")
Sales per employee in the market segment - Neuro
Cassava Sciences is a clinical-stage biopharmaceutical company focused on Alzheimer's disease. Its entire staff is engaged in R&D. This metric reflects the average revenue per employee in the segment. For a company like SAVA without a commercial product, this demonstrates a productivity gap with companies already selling their products and highlights its R&D status.
Sales per employee for the market as a whole
Cassava Sciences (SAVA) is a clinical-stage biopharmaceutical company focused on developing a treatment for Alzheimer's disease. Currently, its staff consists entirely of researchers. This metric is critical for SAVA: it's at zero. Its future growth will mean more than just sales, but a potential breakthrough in the treatment of this complex disease.
Short shares by company, segment and market as a whole
Shares shorted by company Cassava Sciences Inc. (SAVA)
Cassava Sciences has become the epicenter of controversy in biotech. Its Alzheimer's disease candidate, Simufilam, has faced serious allegations of data manipulation. This chart shows the massive number of investor bets that the drug will fail in clinical trials, and that the allegations against the company will ultimately be confirmed, devaluing the company.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cassava-Sciences-Inc.-SAVA&v=1772639130428 "Short Shares Chart for the Company Cassava Sciences Inc. (SAVA)")
Shares shorted by market segment - Neuro
Cassava Sciences (SAVA) is a biopharmaceutical company known for its controversial Alzheimer's drug development. This chart shows the cumulative short position across the entire Alzheimer's drug development sector. It reflects the market's immense skepticism about this complex area of medicine, which has seen decades of failure.
Shares shorted by the overall market
Cassava (SAVA) is one of the most controversial biotechs working on Alzheimer's. When this indicator of *general* market pessimism rises, investors don't just "flee risk"—they flee the "fire." Controversial, speculative stocks like SAVA are the first to be hit by the sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cassava Sciences Inc. (SAVA)
Cassava Sciences is one of the most controversial biotechs, betting on an Alzheimer's drug (Simufilam). The stock is in an all-or-nothing mode. This chart measures this war of opinions. It shows when the euphoria of the "believers" (overbought) or the attacks of the "short sellers" (oversold) reach emotional extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cassava-Sciences-Inc.-SAVA&v=1772639130450 "RSI 14 indicator chart for the company's stock Cassava Sciences Inc. (SAVA)")
RSI 14 Market Segment - Neuro
Cassava (SAVA) is a "biotech" stock, an "Alzheimer's hunter" (with a controversial reputation). The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether SAVA's wild volatility is due to Alzheimer's hype, or is the entire sector overheated?
RSI 14 for the overall market
Cassava Sciences (SAVA), an Alzheimer's drug developer, is critically dependent on this schedule. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to "buy the dream" and invest in the most speculative yet breakthrough projects. In moments of panic, capital flees unprofitable biotech companies.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SAVA (Cassava Sciences Inc.)
Cassava Sciences is a biotech company developing a drug (Simufilam) for the treatment of Alzheimer's disease. The company is in the spotlight due to data controversies. This chart shows the average analyst forecast. Their targets reflect the extremely polarized opinions on Simufilam's chances of success in current trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SAVA-Cassava-Sciences-Inc.&v=1772639130467 "A chart showing analyst consensus forecasts for the expected stock price. SAVA (Cassava Sciences Inc.)")
The difference between the consensus estimate and the actual stock price SAVA (Cassava Sciences Inc.)
Cassava Sciences is one of the most controversial biotech companies. All bets are on its Alzheimer's drug simufilam. This chart illustrates the analyst community's opinion. The huge gap between the price and the target reflects a binary outcome: either a breakthrough or failure in this highly risky R&D project.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SAVA-Cassava-Sciences-Inc.&v=1772639130468 "A chart showing the difference between the consensus forecast and the actual stock price. SAVA (Cassava Sciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Cassava Sciences is one of the most talked-about biotech companies, developing a drug (Simufilam) for the treatment of Alzheimer's disease. This chart reflects analysts' overall expectations for the entire neuroscience sector. It shows whether experts believe a breakthrough in Alzheimer's treatment is possible or whether they consider the sector an R&D "graveyard."
Analysts' consensus forecast for the overall market share price
Cassava Sciences (SAVA) is one of the most talked-about biotech companies. They are developing a drug (Simufilam) for the treatment of Alzheimer's disease, which is fraught with scientific controversy. This chart shows the overall risk appetite, reflecting the market's willingness to fund highly risky R&D projects with blockbuster potential.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cassava Sciences Inc.
Cassava Sciences (SAVA) is a lightning rod in Alzheimer's R&D. The entire company is betting on a single, highly controversial drug (Simufilam), which they claim cures the disease but is widely criticized. This chart is a clear indicator of faith versus skepticism. Its dynamics are a roller coaster, reflecting their new data, their battle with short sellers, and their dialogue with the FDA.
AKIMA Market Segment Index - Neuro
Cassava Sciences is a biotech company best known for developing a drug (Simufilam) for the treatment of Alzheimer's disease. This chart shows the average index for the neuroscience segment. It provides investors with a benchmark for how Cassava's performance, surrounded by both hope and controversy, compares to the sector average.
The AKIM Index for the overall market
Cassava Sciences is a biotech company known for its controversial Alzheimer's drug Simufilam. This chart, which reflects the market average, provides an anchor for reality. It helps assess how this extremely volatile story, driven by news and speculation, fits into the overall macroeconomic picture.
